Loading

Please wait...

Arzerra

Generic Name: ofatumumab (OH fa TOO mue mab)
Brand Names: Arzerra
Arzerra is used to treat chronic lymphocytic leukemia. Learn about side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Arzerra

Set your location
for drug prices near you

Enter your zip code

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Arzerra (ofatumumab) is a monoclonal antibody that affects the actions of the body's immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Arzerra is used to treat chronic lymphocytic leukemia (CLL). In some patients, ofatumumab is given with another medicine called Chlorambucil. Arzerra is sometimes given after other medications have been tried without success. If you have certain risk factors for hepatitis B, Arzerra can cause this condition to come back or get worse, which could lead to liver failure or death. You will need frequent blood tests to check your liver function. Learn more

Arzerra Side Effects

Arzerra Side Effects

Note: This document contains side effect information about ofatumumab. Some of the dosage forms listed on this page may not apply to the brand name Arzerra.

For the Consumer

Applies to ofatumumab: intravenous solution

Warning

Intravenous route (Solution)

Hepatitis B Virus (HBV) reactivation can occur in patients receiving CD20-directed cytolytic antibodies, including ofatumumab, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Progressive Multifocal Leukoencephalopathy (PML) resulting in death can occur in patients receiving CD20-directed cytolytic antibodies, including ofatumumab.

Along with its needed effects, ofatumumab (the active ingredient contained in Arzerra) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ofatumumab:

More common

  • Black, tarry stools
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • blurred vision
  • body aches or pain
  • chest pain
  • chills
  • confusion
  • cough or hoarseness
  • cough producing mucus
  • difficult or labored breathing
  • dizziness
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • ear congestion
  • facial swelling
  • fainting
  • fast heartbeat
  • feeling of warmth
  • headache
  • hives or welts, itching, or skin rash
  • increased sweating
  • lightheadedness
  • loss of voice
  • lower back or side pain
  • nasal congestion
  • nausea or vomiting
  • painful blisters on the trunk of the body
  • painful or difficult urination
  • pale skin
  • rapid weight gain
  • rapid, shallow breathing
  • redness of the face, neck, arms, and occasionally, upper chest
  • runny nose
  • sneezing
  • sore throat
  • tightness in the chest
  • tingling of the hands or feet
  • troubled breathing
  • troubled breathing with exertion
  • ulcers, sores, or white spots in the mouth
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • unusual weight gain or loss
  • weakness

Less common

  • Fast, pounding, or irregular heartbeat or pulse
  • nervousness
  • pounding in the ears
  • slow heartbeat

Incidence not known

  • Blistering, peeling, or loosening of the skin
  • dark urine
  • diarrhea
  • fluid-filled skin blisters
  • joint or muscle pain
  • light-colored stools
  • no blood pressure or pulse
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • sensitivity to the sun
  • skin thinness
  • stopping of heart
  • unconsciousness
  • yellow eyes or skin

Some side effects of ofatumumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Back pain
  • muscle aches
  • redness of the skin
  • trouble sleeping

Less common

  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
  • muscle spasms
  • pain or tenderness around the eyes and cheekbones

For Healthcare Professionals

Applies to ofatumumab: intravenous solution

Hematologic

Very common (10% or more): Neutropenia (up to 27%), anemia (up to 18%)

Common (1% to 10%): Leukopenia, febrile neutropenia, thrombocytopenia

Uncommon (0.1% to 1%): Agranulocytosis, coagulopathy, red cell aplasia, lymphopenia

Respiratory

Very common (10% or more): Upper respiratory tract infection (up to 19%), pneumonia (up to 23%), cough (up to 19%), dyspnea (up to 14%), bronchitis (up to 11%), lower respiratory tract infection

Common (1% to 10%): Sinusitis, nasopharyngitis, bronchospasm, hypoxia, dyspnea, chest discomfort, pharyngolaryngeal pain, nasal congestion

Uncommon (0.1% to 1%): Pulmonary edema

Gastrointestinal

Very common (10% or more): Diarrhea (up to 18%), nausea (up to 11%)

Common (1% to 10%): Upper abdominal pain

Uncommon (0.1% to 1%): Small bowel obstruction

Dermatologic

Very common (10% or more): Rash (e.g., rash, rash macular, rash vesicular) (up to 14%)

Common (1% to 10%): Urticaria, hyperhidrosis, erythema, pruritus

Uncommon (0.1% to 1%): Coagulopathy, red cell aplasia

Postmarketing reports: Stevens-Johnson syndrome, porphyria cutanea tarda

Musculoskeletal

Common (1% to 10%): Arthralgia, back pain, chills, muscle spasms, rigors

Psychiatric

Common (1% to 10%): Insomnia

Nervous system

Common (1% to 10%): Headache

Cardiovascular

Common (1% to 10%): Hypertension, hypotension, tachycardia

Uncommon (0.1% to 1%): Bradycardia

Postmarketing reports: Cardiac arrest (infusion related)

Genitourinary

Common (1% to 10%): Urinary tract infection

Hepatic

Rare (less than 0.1%): Hepatitis B infection and reactivation

Hypersensitivity

Common (1% to 10%): Anaphylactoid reactions, hypersensitivity

Uncommon (0.1% to 1%): Anaphylactic shock, cytokine release syndrome

Immunologic

Common (1% to 10%): Herpes simplex (e.g., oral herpes, herpes, herpes virus infection, genital herpes), influenza, herpes zoster, hypogammaglobulinemia, bacterial infections, viral infections, fungal infections, sepsis (e.g., sepsis, neutropenic sepsis, bacteremia, septic shock)

Uncommon (0.1% to 1%): Immunogenicity

Metabolic

Very common (10% or more):

Common (1% to 10%): Peripheral edema

Uncommon (0.1% to 1%): Tumor lysis syndrome

Other

Very common (10% or more): Pyrexia (up to 20%), fatigue (up to 15%)

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Arzerra (www.drugs.com/arzerra.html).